**Executive Summary**
This document, dated December 9, 2025, details the initiatives by the Department of Pharmaceuticals to increase production capacity through the establishment of bulk drug parks and medical device parks. It also provides updates on the progress and impact of the Production Linked Incentive (PLI) schemes for Bulk Drugs and Pharmaceuticals, with data reported until September 2025. The Department of Commerce's Export Promotion Mission announced in the Union Budget 2025-26 will provide support to exporters.
**Key Points / Main Content**
* **Bulk Drug and Medical Device Parks**
* Bulk drug parks approved in Bharuch (Gujarat), Una (Himachal Pradesh), and Anakapalli (Andhra Pradesh).
* Medical device parks approved in Greater Noida (Uttar Pradesh), Ujjain (Madhya Pradesh), and Kanchipuram (Tamil Nadu).
* Projects are at various stages of execution.
* **PLI Scheme for Bulk Drugs**
* Aims to reduce supply disruption risk of critical APIs and KSMs/DIs.
* Budgetary outlay of ₹6,940 crore.
* Investment of ₹4,763.34 crore made till September 2025.
* Production capacities created for 26 KSMs/DIs/APIs that were primarily imported.
* Cumulative sales of ₹2,315.44 crore reported till September 2025, including exports of ₹508.12 crore.
* **PLI Scheme for Pharmaceuticals**
* Aims to enhance India's manufacturing capabilities, diversification to high-value goods, and incentivize the production of specific drugs.
* Budgetary outlay of ₹15,000 crore.
* Committed investment of ₹17,275 crore substantially exceeded with cumulative investment of ₹40,890 crore made till September 2025.
* Cumulative sales of eligible products worth ₹3,15,492 crore, including exports worth ₹2,02,724 crore.
* Cumulative domestic sales of KSMs/DIs/APIs produced under the scheme worth ₹26,123 crore till September 2025.
* 726 KSMs/DIs/APIs are being manufactured under the scheme, including 191 which have been manufactured for the first time.
* **Export Promotion Mission (Department of Commerce)**
* "Niryat Protsahan” will improve access to affordable trade finance for exporters.
* “Niryat Disha" will support export-readiness through non-financial enablers.
* Will be implemented through a fully digital platform of the Directorate General of Foreign Trade.
**Impact Analysis**
**Pharmaceutical Manufacturers**
* **Impact**: Enhanced production capacity, incentives for domestic manufacturing of critical drugs and pharmaceuticals, and potential for increased exports.
* **Action Required**: Take advantage of PLI schemes, align with export promotion initiatives, and invest in domestic manufacturing of KSMs/DIs/APIs.
**Exporters**
* **Impact**: Improved access to trade finance and support for export readiness.
* **Action Required**: Utilize the Export Promotion Mission and digital platform for trade finance and capacity-building.
**Consumers**
* **Impact**: Potentially reduced reliance on imports for critical drugs and pharmaceuticals, ensuring greater availability of medicines.
* **Action Required**: No immediate action required.
Key Entities Referenced
Department of Pharmaceuticals: The department responsible for implementing schemes related to pharmaceutical production.
PLI Scheme for Pharmaceuticals: A production-linked incentive scheme to enhance India's manufacturing capabilities in the pharmaceutical sector.
PLI Scheme for Bulk Drugs: A production-linked incentive scheme for promoting domestic manufacturing of critical Key Starting Materials, Drug Intermediates, and Active Pharmaceutical Ingredients.
Promotion of Bulk Drug Parks: Scheme to establish bulk drug parks in various districts across India.
Promotion of Medical Device Parks: Scheme to establish medical device parks in various districts across India.
Ministry of Chemicals and Fertilizers :
Department of Pharmaceuticals
Impact of bulk drug parks and medical device
parks
प्रव तथ: 09 DEC 2025 5:24PM by PIB Delhi
With a view to increase production capacity, the Department of Pharmaceuticals has approved projects to
establish bulk drug parks in Bharuch district of Gujarat, Una district of Himachal Pradesh and Anakapalli
district of Andhra Pradesh under its scheme for Promotion of Bulk Drug Parks, and medical parks in
Greater Noida district of Uttar Pradesh, Ujjain district of Madhya Pradesh and Kanchipuram district of
Tamil Nadu under its scheme for Promotion of Medical Device Parks. Currently, these projects are at
various stages of execution.
The details regarding the PLI schemes being implemented by the Government, including the details of
success achieved as a result of their implementation, are as follows:
i. Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key
Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients
(APIs) in India (also known as PLI scheme for Bulk Drugs): The scheme is aimed at avoiding
disruption in supply of critical APIs used to make critical drugs for which there are no alternatives
by reducing supply disruption risk due to excessive dependence on single source. The scheme has a
budgetary outlay of ₹6,940 crore. Till September 2025, investment of ₹4,763.34 crore has already
been made in three and a half years of scheme production period, against an investment
commitment of ₹4,329.95 crore over the period of six years in greenfield projects. Further,
production capacities have been created for 26 KSMs/DIs/APIs, which were earlier primarily
imported. The scheme has resulted in cumulative sales of ₹2,315.44 crore reported till September
2025, including exports of ₹508.12 crore, thereby avoiding imports worth ₹1,807.32 crore.
ii. PLI Scheme for Pharmaceuticals: The scheme is aimed at enhancing India’s manufacturing
capabilities by increasing investment and production in the pharmaceuticals sector and contributing
to product diversification to high-value goods in the pharmaceutical sector and incentivises
production of high-value medicines such as biopharmaceuticals, complex generic drugs, patented
drugs or drugs nearing patent expiry, auto-immune drugs, anti-cancer drugs, etc. as well as
production of KSMs/DIs/APIs other than those notified under the PLI Scheme for Bulk Drugs. It
has a budgetary outlay of ₹15,000 crore. As of September 2025, the committed investment of
₹17,275 crore targeted over the six-year period of the scheme stands substantially exceeded with
cumulative investment of ₹40,890 crore made in three and a half years of scheme production period
in both brownfield and greenfield projects. Further, cumulative sales of eligible products worth
₹3,15,492 crore have been made under the scheme, including exports worth ₹2,02,724 crore.
Cumulative domestic sales of KSMs/DIs/APIs produced under the scheme till September 2025 is
worth ₹26,123 crore and thereby contributing to import avoidance. Further, 726 KSMs/DIs/APIs are
being manufactured under the scheme, including 191 which have been manufactured for the first
time under the scheme.The Department of Commerce has informed that the Export Promotion Mission, announced in the Union
Budget 2025-26, aims to provide comprehensive support to exporters, including those in pharmaceuticals.
Under this, “Niryat Protsahan” will improve access to affordable trade finance for exporters, while “Niryat
Disha” will support export-readiness through non-financial enablers such as compliance and capacity-
building. This will be implemented through a fully digital platform of the Directorate General of Foreign
Trade.
This information was given by Union Minister of State in the Ministry of Chemicals and Fertilizers, Smt.
Anupriya Patel, in a written reply in Rajya Sabha today.
******
PC/NK/PM
(रलीज़ आईडी: 2200939) आगंतुक पटल : 398
इस वज्ञ को इन भाषाओ ंम पढ़: Urdu , ही